<DOC>
	<DOCNO>NCT00279747</DOCNO>
	<brief_summary>A one year double-blind trial investigate efficacy safety meloxicam oral suspension 0.25 mg/kg 0.125 mg/kg administer daily comparison naproxen oral suspension 5 mg/kg administer twice daily child Juvenile Rheumatoid Arthritis .</brief_summary>
	<brief_title>A One Year Double-blind Trial Investigate Efficacy Safety Meloxicam Oral Suspension Juvenile Rheumatoid Arthritis ( JRA/JIA )</brief_title>
	<detailed_description>Objective : In international , multicenter , double-blind , randomize clinical trial evaluate short-term ( 3 month ) long term ( 12 month ) efficacy safety two dos meloxicam oral suspension compare naproxen child oligo polyarticular course juvenile idiopathic arthritis ( JIA ) . Methods : Children active oligo polyarticular course JIA , require therapy NSAID eligible trial . Patients randomly allocate therapy meloxicam oral suspension 0.125 mg/kg body weight single daily dose , meloxicam 0.25 mg/kg body weight single daily dose , naproxen 10 mg/kg body weight two daily dos . The trial drug administer double-blind , double-dummy design 12 month . Response rate determine accord American College Rheumatology Pediatric 30 % definition improvement ( ACR Ped 30 ) . Safety parameter assess evaluation adverse event 3 group . Study Hypothesis : The null hypothesis interest magnitude response regard primary endpoint equivalent treatment group . The alternative difference ( two-sided ) treatment group . Comparison ( ) : Naproxen oral suspension 10 mg/kg body weight .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Meloxicam</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Male female outpatient inpatient age 2 16 year Diagnosis idiopathic arthritis childhood ILAR criterion : Age onset less 16 year Arthritis one joint define swell , swell present limitation range joint movement joint pain tenderness , due primary mechanical disorder Duration disease &gt; 6 week Type onset disease first 6 month classify polyarthritis ( 5 joint ; rheumatoid factor positive negative ) , oligoarthritis ( 4 joint few ) systemic arthritis Oligoarthritic , extend oligoarthritic polyarthritic current course disease Active arthritis define least 2 joint At least 2 abnormal variable 5 remain core set parameter . The physician parent rating must least 10 mm 100 mm VAS scale CHAQ score 0 . Patients require therapy NSAIDs , i.e. , patient fit one follow category : New onset patient Patient remission , experience flare require NSAID Patient insufficient therapeutic effect ( ITE ) intolerability another NSAID ( Naproxen ) must change Written informed permission give parent ( ) subject legally authorise representative accordance local legislation ICH GCP Active assent give patient child capable understanding give information ( apply child reach intellectual age 7 year great ) Patients systemic course JRA ( intermittent fever without rash organ involvement ) current systemic involvement All rheumatic disease cover inclusion criterion Any find indicating patient clinically significant disease JRA time enrollment Patients abnormal , clinically relevant laboratory value relate JRA Pregnancy breast feeding Women childbearing potential use adequate contraception precaution : attention drawn report NSAIDs report decrease effectiveness intrauterine device ( R950164 ) History bleed disorder , gastrointestinal bleeding cerebrovascular bleed Active peptic ulcer within last 6 month Treatment one SAARD/DMARD ( slowacting antirheumatic drug/diseasemodifying antirheumatic drug ) last 3 month prior study entry Change treatment SAARDs/DMARDs last 3 month prior study entry intend change trial duration Change treatment corticosteroid last month prior study entry intend change trial duration exception local therapy uveitis One follow therapy last 3 month prior study entry intend use trial treatment period Systemic treatment ( except intraarticular injection ) corticosteroid dose high 10 mg/day 0.2 mg/kg/day ( prednisone equivalent ) , respectively ( whichever low ) Treatment hydroxychloroquine dose high 10 mg/kg/day Treatment cyclosporine dose high 5 mg/kg/day Treatment methotrexate dose high 15 mg/m2/week Treatment cytotoxic agent , gold compound , Dpenicillamine , Enbrel ( etanercept ) , biologic agent experimentals Intraarticular injection corticosteroid last month prior study entry intend injection first 4 week trial treatment period Concomitant administration NSAIDs ( include topical form skin exception local therapy uveitis ) analgesic agent except paracetamol acetaminophen</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>